Associated Disease Details
| Disease ID: | I11 |
| DO ID: | 5295 |
| Disease Name: | Intestinal disease |
| Definition: | A gastrointestinal system disease that is located_in the intestine. http://en.wikipedia.org/wiki/Human_gastrointestinal_tract |
| Synonyms: | Diarrhoea predominant irritable bowel syndrome; Irritable bowel syndrome with diarrhea; Constipation; Chronic idiopathic constipation; Irritable bowel syndrome characterized by constipation; IBD; IBS |
| Class: | disease of anatomical entity/gastrointestinal system disease |
| Related Drugs: | Rifaximin; Lactulose; Lubiprostone |
| Mechanism: | Regarding NAFLD, experiments using gut microbiota transplants to germ-free animal models showed that fatty liver disease development is determined by gut bacteria. Moreover, the perturbation of the composition of the gut microbiota has been observed in patients suffering from NAFLD. Numerous mechanisms relating the gut microbiome to NAFLD have been proposed, including the dysbiosis-induced dysregulation of gut endothelial barrier function that allows for the translocation of bacterial components and leads to hepatic inflammation. Irritable bowel syndrome (IBS) and non-alcoholic fatty liver disease (NAFLD) are amongst the most common gastrointestinal and liver conditions encountered in primary and secondary care. Recently, there has been interest in the apparent co-incidence of NAFLD in patients with IBS mainly driven by improved understanding of their shared risk factors and pathophysiology. Nonalcoholic fatty liver disease is associated with worse hospitalization outcomes in IBD patients after adjusting for metabolic factors. These data suggest nonmetabolic factors may be implicated in the pathogenesis of NAFLD in IBD patients and may contribute to worsened clinical outcomes. |
| Reference (PMIDs): | 30683985; 35069992; 34374782 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D001 | Acarbose | Chemical drug | DB00284 | MGAM inhibitor;AMY2A inhibitor; AMY2B inhibitor; GAA inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D054 | Calcitriol | Supplement | DB00136 | -- | -- | Under clinical trials | Details |
| D074 | Cholestyramine | Chemical drug | DB01432 | -- | Hypolipidemic drug | Under clinical trials | Details |
| D096 | Dabigatran Etexilate | Chemical drug | DB06695 | thrombin inhibitor | -- | Under clinical trials | Details |
| D120 | Elobixibat | Chemical drug | DB12486 | SLC10A1 inhibitor | Gastrointestinal drug | Under clinical trials | Details |
| D122 | Empagliflozin | Chemical drug | DB09038 | SLC5A2 inhibitor; SGLT-2 inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D126 | Ergocalciferol | Supplement | DB00153 | VDR agonist; VDR modulator | Calcium regulator; Vitamin source drug | Under clinical trials | Details |
| D131 | Ezetimibe | Chemical drug | DB00973 | SOAT1 inhibitor; | Enhance lipid metabolism | Under clinical trials | Details |
| D140 | Folic acid | Supplement | DB00158 | FOLR2 binder | -- | Under clinical trials | Details |
| D155 | Glucagon | Biological drug | DB00040 | GCGR agonist | Antidiabetic drug | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0041 | DB00130 | approved; investigational; nutraceutical | small molecule | L-Glutamine | Therapeutic strategy associated | Details |
| R0049 | DB00146 | approved; nutraceutical | small molecule | Calcifediol | Indication associated | Details |
| R0057 | DB00169 | approved; nutraceutical | small molecule | Cholecalciferol | Therapeutic strategy associated | Details |
| R0071 | DB00193 | approved; investigational | small molecule | Tramadol | Therapeutic strategy associated | Details |
| R0073 | DB00199 | approved; investigational; vet_approved | small molecule | Erythromycin | Indication associated | Details |
| R0074 | DB00201 | approved | small molecule | Caffeine | Indication associated | Details |
| R0093 | DB00244 | approved | small molecule | Mesalazine | Therapeutic strategy associated | Details |
| R0094 | DB00250 | approved; investigational | small molecule | Dapsone | Therapeutic strategy associated | Details |
| R0096 | DB00261 | approved | small molecule | Anagrelide | Therapeutic strategy associated | Details |
| R0116 | DB00326 | approved | small molecule | Calcium glucoheptonate | Indication associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00010 | 35255811 | BMC Gastroenterol | The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial. | Details |
| A00036 | 35249342 | Ann Palliat Med | Risk factors and correlation of colorectal polyps with type 2 diabetes mellitus. | Details |
| A00075 | 35229847 | Food Funct | N-Acetylcysteine alleviates high fat diet-induced hepatic steatosis and liver injury via regulating the intestinal microecology in mice. | Details |
| A00094 | 35222044 | Front Pharmacol | Antibiotic Disruption of the Gut Microbiota Enhances the Murine Hepatic Dysfunction Associated With a High-Salt Diet. | Details |
| A00114 | 35216326 | Int J Mol Sci | New Insights in the Control of Fat Homeostasis: The Role of Neurotensin. | Details |
| A00134 | 35212986 | Methods Mol Biol | Measurement of In Vivo VLDL and Chylomicron Secretion. | Details |
| A00181 | 35195774 | Arch Microbiol | A review on the effect of gut microbiota on metabolic diseases. | Details |
| A00202 | 35188038 | Scand J Gastroenterol | Non-alcoholic fatty liver disease and intestinal immune status: a narrative review. | Details |
| A00248 | 35166723 | Clin Transl Gastroenterol | Relationship between hepatic gene expression, intestinal microbiota and inferred functional metagenomic analysis in NAFLD. | Details |
| A00256 | 35163881 | Molecules | The Anti-Adiposity Mechanisms of Ampelopsin and Vine Tea Extract in High Fat Diet and Alcohol-Induced Fatty Liver Mouse Models. | Details |
| A00257 | 35163821 | Int J Mol Sci | Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. | Details |
| A00269 | 35159371 | Cells | The Origins of NAFLD: The Potential Implication of Intrauterine Life and Early Postnatal Period. | Details |
| A00272 | 35158328 | J Physiol Pharmacol | Current approach to hepatobiliary manifestations in inflammatory bowel disease. | Details |
| A00280 | 35153490 | Int J Tryptophan Res | Intestinal Dysbiosis, the Tryptophan Pathway and Nonalcoholic Steatohepatitis. | Details |
| A00288 | 35152443 | J Food Sci | Bentong ginger oleoresin mitigates liver injury and modulates gut microbiota in mouse with nonalcoholic fatty liver disease induced by high-fat diet. | Details |
| A00332 | 35133032 | FASEB J | TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk. | Details |
| A00337 | 35129841 | Hepatol Res | The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. | Details |
| A00341 | 35127789 | Front Nutr | Lentinan Supplementation Protects the Gut-Liver Axis and Prevents Steatohepatitis: The Role of Gut Microbiota Involved. | Details |
| A00363 | 35119232 | J Basic Clin Physiol Pharmacol | Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data. | Details |
| A00369 | 35115689 | Nat Genet | Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. | Details |